Botulinum Toxin Market to Be worth USD 10.62 Billion by 2030; Increased R&D Activities for Therapeutics to Bolster Market Growth

The Botulinum Toxin market size was valued at USD 7.23 billion in 2022. The market is projected to grow from USD 7.49 billion in 2023 to USD 10.62 billion by 2030, exhibiting a CAGR of 5.1% during the forecast period. Botulinum Toxin Market Size, Share & COVID-19 Impact Analysis, By Application (Therapeutic {Chronic Migraine, Spasticity, Overactive Bladder, Cervical Dystonia, Blepharospasm, and Others} and Aesthetics), By Type (Botulinum Toxin Type A and Botulinum Toxin Type B), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Regional Forecast, 2023-2030. The gram-positive anaerobic bacterium Clostridium botulinum delivers the neurotoxin known as botulinum poison. These products are currently used to manage a variety of medical conditions and cosmetic procedures. These noninvasive cosmetic procedures are in high demand right now. The introduction of new products, an increase in their affordability, and changes to reimbursement policies that include these products for therapeutic use drive the market's expansion.

COVID-19 Outbreak Negatively Impacted Market Growth

The coronavirus pandemic adversely affected the market as a result of the decrease in popularity of restorative techniques during the pandemic. This was due to the healthcare sector's central role in the global pandemic. The lockdown led to a reduction in the number of procedures, which also caused dermatology clinics to close and individuals to be concerned about contracting the virus.

Companies focus on Creating Programs that Increase Awareness Among People to Strengthen Position

On October 2022, the partnership between Galderma and the National Breast Cancer Foundation, Inc. (NBCF) was maintained. During Breast Cancer Awareness Month, Galderma ran a social media campaign that featured the personal stories and treatment journeys of breast cancer survivors who had received Restylane, Dysport (abobotulinum toxin A), or Sculptra.

Expanding Research and Development for Therapeutic and Aesthetic Applications to Drive Market Growth

The products are utilized for both therapeutic and aesthetic purposes. The product's dual application drives the expansion of the market by increasing consumer demand for these goods. For instance, more than 12 million people worldwide will be affected by spasticity by the year 2020, with 80.0% of those affected by cerebral spasticity and 80.0% of those affected by multiple sclerosis. The global botulinum toxin market share grew as a result of the expansion of major pharmaceutical companies' R&D efforts to provide treatment options for such critical diseases.

However, the botulinum toxin market growth is hindered by the introduction of counterfeit goods.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/botulinum-toxin-market-100996

Competitive Landscape

AbbVie Inc. & Ipsen Pharma’s Strong Global Network to Dominate Market

In terms of the competitive landscape, the market has a variety of players, including large, well-established players as well as newer, smaller regional players. In the current scenario, AbbVie, Inc. is the market leader and holds a significant share of the market. BOTOX Cosmetic and BOTOX Therapeutic are just two of the many botulinum toxin products that the company offers. Consequently, it controls the market.

Notable Industry Development:

• November 2022: Hugel, Inc. received marketing approval for 50 and 100 units of Letybo for the indication of glabellar lines from the Therapeutic Goods Administration (TGA) of Australia.

List of Key Players Profiled in the Report

• AbbVie Inc. (U.S.)


• Ipsen Pharma (France)


• Merz Pharma (Germany)


• Medytox (South Korea)


• GALDERMA (Switzerland)


• Lanzhou Institute of Biological Products Co., Ltd. (China)


• HUGEL, Inc. (South Korea)


• Evolus, Inc. (U.S.)


• Revance Therapeutics, Inc. (U.S.)


• Supernus Pharmaceuticals, Inc. (U.S.)

Further Report Findings

• In 2022, sales in the North American market totalled USD 4.77 billion, with the largest share. The increasing number of product launches, the presence of large corporations, and the growing popularity of these practices among locals are all factors that contribute to the region's success.


• Europe caught the second-biggest piece of the pie, owing to the developing inclination for these systems among people in key European nations. In addition, one of the major contributors to the expansion of the European region is the rising amount of money spent on R&D projects for the introduction of new products.

Table of Segmentation